Brainstorm Cell Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Brainstorm Cell Therapeutics Inc. is set to hold its annual meeting on June 25, 2025, seeking stockholder votes on director elections, auditor ratification, warrant share issuance approval, and amendments to stock incentive plans.
OQB
Brainstorm Cell Therapeutics is holding its annual stockholder meeting on June 25, 2025, to vote on director elections, auditor ratification, a common stock issuance proposal, and amendments to its equity incentive plans.
OQB
DEF 14A: Brainstorm Cell Therapeutics Seeks Stockholder Approval for Key Proposals at 2024 Annual Meeting
Brainstorm Cell Therapeutics is holding its 2024 Annual Meeting of Stockholders on September 16, 2024, to vote on several proposals, including the election of directors, ratification of the accounting firm, and amendments to the Certificate of Incorporation and stock incentive plans.